{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:28:05Z","timestamp":1792898885897,"version":"4.5.0"},"reference-count":95,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances have transformed the treatment landscape for relapsed and refractory follicular lymphoma. Although chemotherapy has long served as the backbone of treatment, the availability of novel targeted, immunomodulatory, and immunotherapeutic approaches is challenging its relevance. These approaches have focused on targeting epigenetic regulators, components of the B-cell receptor or its downstream intracellular pathways and the follicular lymphoma tumor microenvironment. The recent development of bispecific antibodies and chimeric antigen receptor T-cell therapies, which target both tumor-associated and host-specific antigens, has enabled a redirection of the immune system, enhancing the innate antitumor immune response. Rational combinations of these strategies are actively being evaluated in the relapsed and refractory setting and will inevitably move forward into earlier lines of treatment. The success of these approaches has led to numerous and parallel options for patients and clinicians. The emerging challenge now lies in how best to approach each individual patient with relapsed or refractory follicular lymphoma, addressing complex decision-making that considers a patient\u2019s previous treatment history, goals of care, clinical and biological characteristics of recurrence, and personal preferences. Understanding the implications of refractory and transformed disease, as well as the timing and biology of relapse will be critical to support a more personalized treatment approach in the modern era.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026018","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T21:16:01Z","timestamp":1755206161000},"page":"1782-1791","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9932","authenticated-orcid":false,"given":"Carla","family":"Casulo","sequence":"first","affiliation":[{"name":"1Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2025100911215939600_bib1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025100911215939600_bib2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1182\/hematology.2022000361","article-title":"Biology of follicular lymphoma: insights and windows of clinical opportunity","volume":"2022","author":"Perrett","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"10","key":"2025100911215939600_bib3","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"31","key":"2025100911215939600_bib4","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"14","key":"2025100911215939600_bib5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2025100911215939600_bib6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2025100911215939600_bib7","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025100911215939600_bib8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025100911215939600_bib9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025100911215939600_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025100911215939600_bib11","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"issue":"11","key":"2025100911215939600_bib12","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"23","key":"2025100911215939600_bib13","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025100911215939600_bib14","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025100911215939600_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"suppl 1","key":"2025100911215939600_bib16","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2024-201078","article-title":"Outcomes in early relapse of follicular lymphoma versus early histologic transformation following firstline immunochemotherapy in follicular lymphoma [abstract]","volume":"144","author":"Casulo","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025100911215939600_bib17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.18522","article-title":"Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome","volume":"200","author":"Munta\u00f1ola","year":"2023","journal-title":"Br J Haematol"},{"issue":"7","key":"2025100911215939600_bib18","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","article-title":"Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life","volume":"99","author":"Sortais","year":"2020","journal-title":"Ann Hematol"},{"issue":"4","key":"2025100911215939600_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bneo.2024.100044","article-title":"Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy","volume":"1","author":"Tobin","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"suppl 1","key":"2025100911215939600_bib20","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1182\/blood-2023-190325","article-title":"Impact of early histological transformation on survival in patients with follicular lymphoma [abstract]","volume":"142","author":"Luttwak","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025100911215939600_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clml.2022.09.003","article-title":"Risk factors for and outcomes of follicular lymphoma histological transformation at first progression in the GALLIUM study","volume":"23","author":"Casulo","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"2025100911215939600_bib22","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic specialized program of research excellence molecular epidemiology resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025100911215939600_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40364-023-00525-1","article-title":"Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study","volume":"11","author":"Vaughn","year":"2023","journal-title":"Biomark Res"},{"issue":"9","key":"2025100911215939600_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"22","key":"2025100911215939600_bib25","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025100911215939600_bib26","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1097\/HS9.0000000000000745","article-title":"A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL)","volume":"6","author":"Salles","year":"2022","journal-title":"Hemasphere"},{"issue":"5","key":"2025100911215939600_bib27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO Group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"2025100911215939600_bib28","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025100911215939600_bib29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"2025100911215939600_bib30","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"22","key":"2025100911215939600_bib31","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood.V128.22.2953.2953","article-title":"Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB studies 50402, 50701 and 50803 (Alliance) [abstract]","volume":"128","author":"Lansigan","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2025100911215939600_bib32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/bloodadvances.2024014053","article-title":"Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium","volume":"9","author":"Day","year":"2025","journal-title":"Blood Adv"},{"issue":"30","key":"2025100911215939600_bib33","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025100911215939600_bib34","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1182\/bloodadvances.2020001942","article-title":"A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy","volume":"4","author":"Maloney","year":"2020","journal-title":"Blood Adv"},{"issue":"15","key":"2025100911215939600_bib35","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 18","key":"2025100911215939600_bib36","article-title":"GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma [abstract]","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025100911215939600_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canrad.2017.09.003","article-title":"Radiotherapy of relapse-refractory follicular lymphoma","volume":"22","author":"Grignano","year":"2018","journal-title":"Cancer Radiother"},{"issue":"1","key":"2025100911215939600_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2003.05.128","article-title":"Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B","volume":"21","author":"Peterson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025100911215939600_bib39","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/bjh.15057","article-title":"A retrospective study of R-DHAP\/Ox for early progressing follicular lymphoma","volume":"183","author":"Ghione","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2025100911215939600_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.2154","article-title":"Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study","volume":"33","author":"Martinelli","year":"2015","journal-title":"Hematol Oncol"},{"issue":"8","key":"2025100911215939600_bib41","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3109\/10428194.2012.747679","article-title":"Retreatment with bendamustine-containing regimens in patients with relapsed\/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions","volume":"54","author":"Weide","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025100911215939600_bib42","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3109\/10428194.2014.921298","article-title":"Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma","volume":"56","author":"Ito","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025100911215939600_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025100911215939600_bib44","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"2025100911215939600_bib45","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025100911215939600_bib46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.hoc.2020.02.007","article-title":"Immunomodulatory agents in follicular lymphoma","volume":"34","author":"Ysebaert","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"16","key":"2025100911215939600_bib47","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.3390\/ijms22168572","article-title":"Immunomodulatory drugs for the treatment of B cell malignancies","volume":"22","author":"Ioannou","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2025100911215939600_bib48","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2025100911215939600_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br J Haematol"},{"issue":"14","key":"2025100911215939600_bib50","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood-2018-05-853499","article-title":"An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed\/refractory follicular B-cell lymphoma","volume":"132","author":"Morschhauser","year":"2018","journal-title":"Blood"},{"issue":"14","key":"2025100911215939600_bib51","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"31","key":"2025100911215939600_bib52","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025100911215939600_bib53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2022-158631","article-title":"Five-year results and overall survival update from the phase 3 randomized study augment: lenalidomide plus rituximab (R2) vs rituximab plus placebo in patients with relapsed\/refractory indolent non-Hodgkin lymphoma [abstract]","volume":"140","author":"Leonard","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025100911215939600_bib54","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"suppl 2","key":"2025100911215939600_bib55","article-title":"Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND) [abstract]","volume":"144","author":"Sehn","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025100911215939600_bib56","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025100911215939600_bib57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2025100911215939600_bib58","first-page":"1","article-title":"PI3k inhibitors in NHL and CLL: an unfulfilled promise","volume":"13","author":"Bou Zeid","year":"2023","journal-title":"Blood Lymphat Cancer"},{"issue":"S3","key":"2025100911215939600_bib59","article-title":"S1608: randomized phase II trial comparing lenalidomide\/obinutuzumab and umbralisib\/obinutuzumab with chemoimmunotherapy in early progressing follicular lymphoma (POD24) [abstract]","volume":"43","author":"Barr","year":"2025","journal-title":"Hematological Oncol"},{"issue":"1","key":"2025100911215939600_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"17","key":"2025100911215939600_bib61","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2025100911215939600_bib62","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025100911215939600_bib63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study [abstract]","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025100911215939600_bib64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood-2024-200262","article-title":"Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the Epcore NHL-2 trial [abstract]","volume":"144","author":"Falchi","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025100911215939600_bib65","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a national LymphoCare study and Center for International Blood and Marrow Transplant research analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2025100911215939600_bib66","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"issue":"6","key":"2025100911215939600_bib67","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"2025100911215939600_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark Res"},{"issue":"5","key":"2025100911215939600_bib69","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response","volume":"37","author":"Beguelin","year":"2020","journal-title":"Cancer Cell"},{"issue":"18","key":"2025100911215939600_bib70","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2025100911215939600_bib71","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100911215939600_bib72","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2022-166991","article-title":"Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed\/refractory follicular lymphoma: phase 1b results of symphony-1","volume":"140","author":"Batlevi","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025100911215939600_bib73","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2025100911215939600_bib74","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"33","key":"2025100911215939600_bib75","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2025100911215939600_bib76","doi-asserted-by":"crossref","first-page":"TPS7590","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7590","article-title":"MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025100911215939600_bib77","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood-2024-194627","article-title":"5-year follow-up analysis from ZUMA-5: a phase 2 trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma [abstract]","volume":"144","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2025100911215939600_bib78","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/bloodadvances.2021004535","article-title":"The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas","volume":"8","author":"Haydu","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2025100911215939600_bib79","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"22","key":"2025100911215939600_bib80","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"2025100911215939600_bib81","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025100911215939600_bib82","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"2025100911215939600_bib83","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2025100911215939600_bib84","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2024-197897","article-title":"Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study [abstract]","volume":"144","author":"Shadman","year":"2024","journal-title":"Blood"},{"issue":"S3","key":"2025100911215939600_bib85","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1002\/hon.70094_240","article-title":"Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed\/ refractory follicular lymphoma [abstract]","volume":"43","author":"Linton","year":"2025","journal-title":"Hematological Oncology"},{"issue":"7","key":"2025100911215939600_bib86","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2025100911215939600_bib87","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2024-194612","article-title":"Subcutaneous mosunetuzumab leads to high rates of durable responses, low rates of cytokine release syndrome, and non-inferior exposure compared with intravenous administration in patients with relapsed\/refractory follicular lymphoma: primary analysis of a pivotal phase II [abstract]","volume":"144","author":"Bartlett","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025100911215939600_bib88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2008.07067.x","article-title":"Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma","volume":"141","author":"Ingram","year":"2008","journal-title":"Br J Haematol"},{"issue":"21","key":"2025100911215939600_bib89","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1158\/1078-0432.CCR-21-1377","article-title":"Nine-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant","volume":"27","author":"Khouri","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2025100911215939600_bib90","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"2025100911215939600_bib91","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","article-title":"Reduced-intensity allografting as first transplantation approach in relapsed\/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors","volume":"21","author":"Klyuchnikov","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2025100911215939600_bib92","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2025100911215939600_bib93","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.2024024526","article-title":"Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma","volume":"144","author":"Crochet","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025100911215939600_bib94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025100911215939600_bib95","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/15\/1782\/2415869\/blood_bld-2024-026018-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/15\/1782\/2415869\/blood_bld-2024-026018-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:22:14Z","timestamp":1760023334000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/15\/1782\/546730\/Treatment-of-relapsed-and-refractory-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":95,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,10,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026018","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,9]]},"published":{"date-parts":[[2025,10,9]]}}}